H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

October 8, 2026 7:00 AM

H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $25.00 price target on Ultragenyx Pharma (NASDAQ: RARE).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found